MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion
MedRhythms (NASDAQ:LFWD) has appointed Larry Jasinski as its new Chief Executive Officer, effective immediately. Jasinski, former CEO of Lifeward, brings over 30 years of executive leadership in medical devices and neurotechnology. Co-founder Brian Harris transitions to Chief Scientific Officer after successfully leading the company through product development, FDA listings, and CMS benefit category assignments.
The appointment comes as MedRhythms prepares for national expansion of its FDA-listed Class II devices: InTandem® for chronic stroke and Movive™ for Parkinson's disease. Under Jasinski's leadership, the company aims to accelerate market adoption of its prescription music platform and expand access to its neurotherapeutics for walking and mobility improvements.
Jasinski's track record includes leading Lifeward through a successful IPO and securing national reimbursement for the first exoskeleton system for spinal cord injury.
MedRhythms (NASDAQ:LFWD) ha nominato Larry Jasinski come nuovo Amministratore Delegato, con effetto immediato. Jasinski, ex CEO di Lifeward, vanta oltre 30 anni di esperienza nella leadership esecutiva nel settore dei dispositivi medici e della neurotecnologia. Il cofondatore Brian Harris assume il ruolo di Chief Scientific Officer dopo aver guidato con successo l'azienda nello sviluppo dei prodotti, nelle approvazioni FDA e nelle assegnazioni delle categorie di beneficio CMS.
La nomina arriva mentre MedRhythms si prepara all'espansione nazionale dei suoi dispositivi di Classe II approvati dalla FDA: InTandem® per l'ictus cronico e Movive™ per il morbo di Parkinson. Sotto la guida di Jasinski, l'azienda punta ad accelerare l'adozione sul mercato della sua piattaforma musicale su prescrizione e ad ampliare l'accesso alle sue neuroterapie per migliorare camminata e mobilità.
Il percorso professionale di Jasinski include la conduzione di Lifeward verso un IPO di successo e l'ottenimento del rimborso nazionale per il primo sistema di esoscheletro destinato alle lesioni del midollo spinale.
MedRhythms (NASDAQ:LFWD) ha nombrado a Larry Jasinski como su nuevo Director Ejecutivo, con efecto inmediato. Jasinski, ex CEO de Lifeward, aporta más de 30 años de liderazgo ejecutivo en dispositivos médicos y neurotecnología. El cofundador Brian Harris pasa a ser Director Científico tras haber liderado exitosamente el desarrollo de productos, las aprobaciones de la FDA y las asignaciones de categorías de beneficios de CMS.
Este nombramiento llega mientras MedRhythms se prepara para la expansión nacional de sus dispositivos de Clase II aprobados por la FDA: InTandem® para el ictus crónico y Movive™ para la enfermedad de Parkinson. Bajo el liderazgo de Jasinski, la empresa busca acelerar la adopción en el mercado de su plataforma de música con prescripción y ampliar el acceso a sus neuroterapéuticos para mejorar la marcha y la movilidad.
La trayectoria de Jasinski incluye haber llevado a Lifeward a una exitosa salida a bolsa y asegurar el reembolso nacional para el primer sistema de exoesqueleto para lesiones de la médula espinal.
MedRhythms (NASDAQ:LFWD)는 즉시 발효되는 새로운 최고경영자(CEO)로 Larry Jasinski를 임명했습니다. Lifeward의 전 CEO인 Jasinski는 의료기기 및 신경기술 분야에서 30년 이상의 경영 리더십 경험을 보유하고 있습니다. 공동창립자인 Brian Harris는 제품 개발, FDA 승인, CMS 혜택 분류 지정 등을 성공적으로 이끈 후 최고과학책임자(CSO)로 자리를 옮겼습니다.
이 임명은 MedRhythms가 FDA 승인된 클래스 II 기기인 만성 뇌졸중 치료용 InTandem®과 파킨슨병 치료용 Movive™의 전국적 확장을 준비하는 가운데 이루어졌습니다. Jasinski의 리더십 하에 회사는 처방 음악 플랫폼의 시장 도입을 가속화하고 보행 및 이동성 개선을 위한 신경 치료제의 접근성을 확대하는 것을 목표로 하고 있습니다.
Jasinski의 경력에는 Lifeward를 성공적인 IPO로 이끌고 척수 손상용 최초 외골격 시스템의 국가 보험 급여를 확보한 업적이 포함되어 있습니다.
MedRhythms (NASDAQ:LFWD) a nommé Larry Jasinski comme nouveau Directeur Général, avec effet immédiat. Jasinski, ancien PDG de Lifeward, apporte plus de 30 ans d'expérience en leadership exécutif dans les dispositifs médicaux et la neurotechnologie. Le cofondateur Brian Harris devient Directeur Scientifique après avoir mené avec succès l'entreprise à travers le développement de produits, les enregistrements FDA et les classifications CMS des catégories de bénéfices.
Cette nomination intervient alors que MedRhythms se prépare à l'expansion nationale de ses dispositifs de classe II approuvés par la FDA : InTandem® pour les AVC chroniques et Movive™ pour la maladie de Parkinson. Sous la direction de Jasinski, l'entreprise vise à accélérer l'adoption sur le marché de sa plateforme musicale sur ordonnance et à élargir l'accès à ses neurothérapeutiques pour améliorer la marche et la mobilité.
Le parcours de Jasinski inclut la direction de Lifeward lors d'une introduction en bourse réussie et l'obtention du remboursement national pour le premier système d'exosquelette destiné aux lésions de la moelle épinière.
MedRhythms (NASDAQ:LFWD) hat Larry Jasinski mit sofortiger Wirkung zum neuen Chief Executive Officer ernannt. Jasinski, ehemaliger CEO von Lifeward, bringt über 30 Jahre Führungserfahrung im Bereich Medizintechnik und Neurotechnologie mit. Mitgründer Brian Harris wechselt nach erfolgreicher Führung des Unternehmens durch Produktentwicklung, FDA-Zulassungen und CMS-Leistungszuweisungen in die Rolle des Chief Scientific Officer.
Die Ernennung erfolgt, während MedRhythms sich auf die nationale Expansion seiner von der FDA zugelassenen Klasse-II-Geräte vorbereitet: InTandem® für chronischen Schlaganfall und Movive™ für Parkinson. Unter Jasinskis Führung will das Unternehmen die Markteinführung seiner verschreibungspflichtigen Musikplattform beschleunigen und den Zugang zu seinen Neurotherapeutika zur Verbesserung von Gehen und Mobilität erweitern.
Jasinskis Erfolgsgeschichte umfasst die Leitung von Lifeward durch einen erfolgreichen Börsengang und die Sicherung der nationalen Erstattung für das erste Exoskelettsystem bei Rückenmarksverletzungen.
- Appointment of experienced CEO with proven track record in neurorehabilitation and successful IPO execution
- Both flagship products (InTandem® and Movive™) are FDA-listed Class II devices with federal healthcare distribution approval
- Established CMS benefit category and unique HCPCPS code secured for products
- Company has strong clinical data foundation and good product margins
- Leadership transition may cause temporary operational adjustments
- National expansion phase ahead requires significant execution and resource allocation
Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer
Mr. Jasinski brings more than three decades of executive leadership in the medical device and neurotechnology industries. Most recently, he served as CEO of Lifeward (NASDAQ: LFWD), formerly ReWalk Robotics, where he led the company through a successful IPO and secured national reimbursement for the first exoskeleton system for spinal cord injury. Prior to that, he was President and CEO of Soteira, Inc., which was acquired by Globus Medical in 2012.
"After a rigorous, international search process, the Board of Directors Search Committee unanimously and enthusiastically selected Larry as MedRhythms' next CEO. The Board and major investors are excited to welcome Larry to MedRhythms and eagerly look forward to his leadership of our great team into the next phase of company growth," said Jean Hoffman, Board Member and Chair of the CEO Search Committee.
"MedRhythms has innovative fundamental technology, well-established published clinical data on effectiveness, an elegant and easy-to-use product with good margins, will operate in sizable market segments and has gained CMS and other coverage," said Larry Jasinski. "MedRhythms will improve many lives and is positioned to become a valuable business entity. I'm honored to join this mission-driven team and look forward to accelerating our growth and impact on patients' lives."
Co-founder Brian Harris added, "MedRhythms was founded on the vision and mission of transforming patients' lives and Larry has dedicated his career to that same mission. His experience is an ideal fit for the next important phase of the company, and I look forward to working with him to continue to advance the company's mission and increase its impact in bringing important care to patients who need and deserve it."
Jasinski's appointment marks a critical inflection point for MedRhythms, as the company prepares for national expansion of its home-use products for walking impairments: InTandem®, for chronic stroke, and Movive™, for Parkinson's disease. Both products are FDA-listed, Class II devices and are now available for federal healthcare distribution. As CEO, Jasinski will lead MedRhythms' strategic expansion, accelerate market adoption and build on its robust clinical foundation to bring the company's groundbreaking platform to more patients with chronic health and mobility conditions.
About MedRhythms
MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. The company is developing a pipeline of products across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. In 2021, the company partnered with Universal Music Group and raised a Series B financing round led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in
For more information, visit www.medrhythms.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/medrhythms-appoints-larry-jasinski-as-chief-executive-officer-to-lead-next-phase-of-growth-and-commercial-expansion-302498926.html
SOURCE MedRhythms
FAQ
Who is the new CEO of MedRhythms (NASDAQ:LFWD) and what is his background?
What are MedRhythms' main products and their FDA status?
What is Brian Harris's new role at MedRhythms?
What regulatory approvals has MedRhythms secured for its products?
What is MedRhythms' main technology focus?
